CN114901697A - 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 - Google Patents

一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 Download PDF

Info

Publication number
CN114901697A
CN114901697A CN202180007833.9A CN202180007833A CN114901697A CN 114901697 A CN114901697 A CN 114901697A CN 202180007833 A CN202180007833 A CN 202180007833A CN 114901697 A CN114901697 A CN 114901697A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
heavy chain
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180007833.9A
Other languages
English (en)
Other versions
CN114901697B (zh
Inventor
白义
周俊杰
刘思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BEIJING JINGYI TAIXIANG TECHNOLOGY DEVELOPMENT CO LTD
Beijing Dongfang Baitai Biotechnology Co ltd
Original Assignee
BEIJING JINGYI TAIXIANG TECHNOLOGY DEVELOPMENT CO LTD
Beijing Dongfang Baitai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BEIJING JINGYI TAIXIANG TECHNOLOGY DEVELOPMENT CO LTD, Beijing Dongfang Baitai Biotechnology Co ltd filed Critical BEIJING JINGYI TAIXIANG TECHNOLOGY DEVELOPMENT CO LTD
Publication of CN114901697A publication Critical patent/CN114901697A/zh
Application granted granted Critical
Publication of CN114901697B publication Critical patent/CN114901697B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

涉及生物医药领域，具体提供了一种抗LAG‑3的单克隆抗体、其抗原结合片段及其应用，其包括重链可变区和轻链可变区，单克隆抗体或其抗原结合片段选自A‑1、A‑2、A‑3、A‑4中任意一种。提供的单克隆抗体能够特异性结合LAG‑3，亲和力较高，且具有很好的生物学活性，能够用于治疗多种癌症或者免疫疾病，癌症包括白血病、肺癌、胃癌、食道癌、卵巢癌、头颈癌、黑色素瘤、肾癌、乳腺癌、结直肠癌、肝癌、胰腺癌或膀胱癌，免疫疾病包括银屑病、克罗恩病、类风湿性关节炎、原发性胆汁性肝硬化、系统性红斑狼疮、多发性硬化症、溃疡性结肠炎和自身免疫性肝炎。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202180007833.9A 2020-12-10 2021-11-29 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 Active CN114901697B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020114365815 2020-12-10
CN202011436581.5A CN114621345B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
PCT/CN2021/133941 WO2022121720A1 (zh) 2020-12-10 2021-11-29 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用

Publications (2)

Publication Number Publication Date
CN114901697A true CN114901697A (zh) 2022-08-12
CN114901697B CN114901697B (zh) 2022-12-13

Family

ID=81895398

Family Applications (5)

Application Number Title Priority Date Filing Date
CN202011436581.5A Active CN114621345B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN202211155576.6A Active CN115819585B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN202211155539.5A Active CN116514972B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN202211155535.7A Active CN116514971B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN202180007833.9A Active CN114901697B (zh) 2020-12-10 2021-11-29 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CN202011436581.5A Active CN114621345B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN202211155576.6A Active CN115819585B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN202211155539.5A Active CN116514972B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN202211155535.7A Active CN116514971B (zh) 2020-12-10 2020-12-10 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用

Country Status (9)

Country Link
US (1) US20240025994A1 (zh)
EP (1) EP4242234A1 (zh)
JP (1) JP2023552621A (zh)
KR (1) KR20230118922A (zh)
CN (5) CN114621345B (zh)
AU (1) AU2021398061A1 (zh)
CA (1) CA3204858A1 (zh)
IL (1) IL303443A (zh)
WO (1) WO2022121720A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819585A (zh) * 2020-12-10 2023-03-21 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN115869399A (zh) * 2022-12-28 2023-03-31 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用
CN116199779A (zh) * 2022-12-08 2023-06-02 北京东方百泰生物科技股份有限公司 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327177B (zh) * 2022-06-24 2024-06-25 东莞市朋志生物科技有限公司 抗脂联素抗体、检测脂联素的试剂和试剂盒
CN117447595B (zh) * 2022-07-26 2024-06-28 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017219995A1 (zh) * 2016-06-23 2017-12-28 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
US20180127499A1 (en) * 2016-10-11 2018-05-10 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2018152687A1 (en) * 2017-02-22 2018-08-30 I-Mab Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
CN109475617A (zh) * 2017-02-22 2019-03-15 天境生物 抗lag-3抗体及其应用
WO2020173378A1 (zh) * 2019-02-28 2020-09-03 三生国健药业（上海）股份有限公司 结合人lag-3的抗体、其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103525868B (zh) 2013-10-17 2015-01-21 百泰生物药业有限公司 哺乳动物细胞高效表达载体的构建及应用
CA2937503A1 (en) * 2014-01-28 2015-08-06 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
US11285207B2 (en) * 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
CN111542546B (zh) * 2018-01-18 2022-08-16 四川科伦博泰生物医药股份有限公司 抗lag-3抗体及其用途
TWI833738B (zh) * 2018-03-20 2024-03-01 中國大陸商上海藥明生物技術有限公司 新型抗lag-3抗體多肽
CN110606892B (zh) * 2018-06-14 2023-09-26 华博生物医药技术（上海）有限公司 一种高亲和力高生物活性的lag-3抗体及其应用
CN114621345B (zh) * 2020-12-10 2022-11-29 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN114617961B (zh) * 2020-12-10 2022-12-02 北京东方百泰生物科技股份有限公司 一种抗lag-3单克隆抗体的注射制剂
CN114621344B (zh) * 2020-12-10 2022-08-30 北京东方百泰生物科技股份有限公司 一种抗lag-3单克隆抗体的纯化方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017219995A1 (zh) * 2016-06-23 2017-12-28 江苏恒瑞医药股份有限公司 Lag-3抗体、其抗原结合片段及其医药用途
US20180127499A1 (en) * 2016-10-11 2018-05-10 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CN110023337A (zh) * 2016-10-11 2019-07-16 艾吉纳斯公司 抗lag-3抗体及其使用方法
WO2018152687A1 (en) * 2017-02-22 2018-08-30 I-Mab Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof
CN109475617A (zh) * 2017-02-22 2019-03-15 天境生物 抗lag-3抗体及其应用
WO2020173378A1 (zh) * 2019-02-28 2020-09-03 三生国健药业（上海）股份有限公司 结合人lag-3的抗体、其制备方法和用途

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819585A (zh) * 2020-12-10 2023-03-21 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN115819585B (zh) * 2020-12-10 2023-06-02 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN116199779A (zh) * 2022-12-08 2023-06-02 北京东方百泰生物科技股份有限公司 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用
CN116199779B (zh) * 2022-12-08 2023-08-11 北京东方百泰生物科技股份有限公司 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用
CN115869399A (zh) * 2022-12-28 2023-03-31 广州誉衡生物科技有限公司 一种药物组合物和药物制剂及其在治疗非小细胞肺癌中的应用

Also Published As

Publication number Publication date
CN114621345B (zh) 2022-11-29
CN115819585A (zh) 2023-03-21
CA3204858A1 (en) 2022-06-16
CN116514971B (zh) 2023-10-27
CN114901697B (zh) 2022-12-13
CN116514972B (zh) 2023-10-27
WO2022121720A1 (zh) 2022-06-16
AU2021398061A9 (en) 2023-08-24
EP4242234A1 (en) 2023-09-13
JP2023552621A (ja) 2023-12-18
KR20230118922A (ko) 2023-08-14
IL303443A (en) 2023-08-01
CN114621345A (zh) 2022-06-14
CN116514972A (zh) 2023-08-01
CN115819585B (zh) 2023-06-02
US20240025994A1 (en) 2024-01-25
CN116514971A (zh) 2023-08-01
AU2021398061A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CN114901697B (zh) 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
CN110964111B (zh) 一种抗pd-l1单克隆抗体、其抗原结合片段及其应用
CN109776678A (zh) 一种人源化pd-l1单克隆抗体、其制备方法和应用
CN110655579B (zh) 一种新型抗ctla-4单克隆抗体及其应用
CN107840885B (zh) Gm-csf抗体及其用途
CN113402607A (zh) 一种抗lap单克隆抗体、其抗原结合片段及其应用
WO2024022008A1 (zh) 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用
CN117447593B (zh) 一种抗Siglec-15单克隆抗体
CN114621344B (zh) 一种抗lag-3单克隆抗体的纯化方法
CN114617961B (zh) 一种抗lag-3单克隆抗体的注射制剂
CN107840886B (zh) Gm-csf抗体及其用途
CN116199779B (zh) 一种抗lilrb4单克隆抗体、其抗原结合片段及其应用
US20230159652A1 (en) Transferrin receptor 1 targeting for carcinogenesis prevention
CN115819587A (zh) 一种抗nkg2a单克隆抗体及其应用
CN115947850A (zh) 一种靶向lilrb4的单克隆抗体
CN116284393A (zh) 一种靶向lilrb4的单克隆抗体
CN118243802A (zh) 一种抗Siglec-15单克隆抗体电荷异质性的检测方法
CN116178550A (zh) 一种抗lilrb4单克隆抗体
CN116143922A (zh) 一种抗lilrb4单克隆抗体
CN116023498A (zh) 一种抗lilrb4单克隆抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant